Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the sale, the chief financial officer directly owned 40,036 shares in the company, valued at $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $52.64, for a total value of $316,787.52.
• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $43.80, for a total value of $263,588.40.

Enliven Therapeutics Stock Down 1.1%

NASDAQ:ELVN traded down $0.68 during trading hours on Wednesday, reaching $59.39. The company had a trading volume of 939,429 shares, compared to its average volume of 1,258,195. The stock has a 50-day moving average of $51.90 and a two-hundred day moving average of $41.38. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The firm has a market capitalization of $4.35 billion, a PE ratio of -35.56 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Enliven Therapeutics in the second quarter worth $221,255,000. Vestal Point Capital LP lifted its position in Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Siren L.L.C. purchased a new stake in Enliven Therapeutics during the 1st quarter valued at $29,252,000. Jupiter Topco LLC bought a new stake in shares of Enliven Therapeutics in the second quarter worth about $30,617,000. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Enliven Therapeutics during the first quarter valued at approximately $23,007,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

ELVN has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. HC Wainwright upped their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Mizuho increased their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday. JonesTrading increased their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, William Blair initiated coverage on shares of Enliven Therapeutics in a report on Tuesday. They set an “outperform” rating on the stock. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.